WO2020214510A1 - Pharmaceutical formulations containing p2y14 antagonists - Google Patents
Pharmaceutical formulations containing p2y14 antagonists Download PDFInfo
- Publication number
- WO2020214510A1 WO2020214510A1 PCT/US2020/027882 US2020027882W WO2020214510A1 WO 2020214510 A1 WO2020214510 A1 WO 2020214510A1 US 2020027882 W US2020027882 W US 2020027882W WO 2020214510 A1 WO2020214510 A1 WO 2020214510A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pptn
- pharmaceutical formulation
- less
- body weight
- concentrations
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 38
- 230000003042 antagnostic Effects 0.000 title abstract description 48
- 239000005557 antagonist Substances 0.000 title abstract description 48
- FOECKIWHCOYYFL-UHFFFAOYSA-N 4-(4-piperidin-4-ylphenyl)-7-[4-(trifluoromethyl)phenyl]naphthalene-2-carboxylic acid Chemical compound C=12C=CC(C=3C=CC(=CC=3)C(F)(F)F)=CC2=CC(C(=O)O)=CC=1C(C=C1)=CC=C1C1CCNCC1 FOECKIWHCOYYFL-UHFFFAOYSA-N 0.000 claims abstract description 135
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 30
- 150000005209 naphthoic acids Chemical class 0.000 claims abstract description 17
- 206010038428 Renal disease Diseases 0.000 claims abstract description 9
- 239000011780 sodium chloride Substances 0.000 claims description 47
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 26
- -1 naphthoic acid derivative salt Chemical class 0.000 claims description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000002953 phosphate buffered saline Substances 0.000 claims description 12
- 229940086735 succinate Drugs 0.000 claims description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 229960001295 Tocopherol Drugs 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229930003799 tocopherols Natural products 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 82
- 206010061218 Inflammation Diseases 0.000 abstract description 24
- 230000004054 inflammatory process Effects 0.000 abstract description 24
- 230000000268 renotropic Effects 0.000 abstract description 21
- 102100010468 P2RY14 Human genes 0.000 abstract description 17
- 101710037776 P2RY14 Proteins 0.000 abstract description 17
- 201000006370 kidney failure Diseases 0.000 abstract description 3
- 230000037396 body weight Effects 0.000 description 83
- 241000700159 Rattus Species 0.000 description 71
- 238000001990 intravenous administration Methods 0.000 description 66
- 238000001802 infusion Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 47
- 238000009472 formulation Methods 0.000 description 41
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 40
- 210000002700 Urine Anatomy 0.000 description 38
- 210000002381 Plasma Anatomy 0.000 description 28
- 125000000217 alkyl group Chemical group 0.000 description 24
- 238000011002 quantification Methods 0.000 description 24
- 208000009304 Acute Kidney Injury Diseases 0.000 description 23
- 206010038436 Renal failure acute Diseases 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 22
- 235000019000 fluorine Nutrition 0.000 description 22
- 230000036470 plasma concentration Effects 0.000 description 18
- 239000000523 sample Substances 0.000 description 17
- 125000001424 substituent group Chemical group 0.000 description 15
- 210000003734 Kidney Anatomy 0.000 description 13
- 206010063837 Reperfusion injury Diseases 0.000 description 13
- 125000001153 fluoro group Chemical group F* 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- 229940109239 Creatinine Drugs 0.000 description 9
- 125000004432 carbon atoms Chemical group C* 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 239000011737 fluorine Chemical group 0.000 description 9
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 210000004369 Blood Anatomy 0.000 description 8
- 206010022114 Injury Diseases 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-α-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000007675 cardiac surgery Methods 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 206010061255 Ischaemia Diseases 0.000 description 6
- 230000036151 Urine output Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000006172 buffering agent Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000003000 nontoxic Effects 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000002829 reduced Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 5
- 230000003907 kidney function Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 4
- 206010003816 Autoimmune disease Diseases 0.000 description 4
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 description 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 4
- 206010012601 Diabetes mellitus Diseases 0.000 description 4
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 4
- 206010061835 Diabetic nephropathy Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000010159 IGA Glomerulonephritis Diseases 0.000 description 4
- 206010021263 IgA nephropathy Diseases 0.000 description 4
- 210000001439 Intercalated cell Anatomy 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 206010038540 Renal tubular necrosis Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 201000001174 autosomal dominant polycystic kidney disease Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 4
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 230000024924 glomerular filtration Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 210000000056 organs Anatomy 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000001083 Kidney Disease Diseases 0.000 description 3
- 229940049964 Oleate Drugs 0.000 description 3
- 210000002966 Serum Anatomy 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- 108060008443 TPPP Proteins 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 150000002402 hexoses Chemical class 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 230000001146 hypoxic Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N oxane Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 230000036231 pharmacokinetics Effects 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000003068 static Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 2
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 2
- 206010001843 Alport's syndrome Diseases 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 240000005781 Arachis hypogaea Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N Bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
- 102100009791 COL4A5 Human genes 0.000 description 2
- 101710038499 COL4A5 Proteins 0.000 description 2
- 206010007515 Cardiac arrest Diseases 0.000 description 2
- 206010007554 Cardiac failure Diseases 0.000 description 2
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 2
- 230000037250 Clearance Effects 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 210000000585 Glomerular Basement Membrane Anatomy 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010061989 Glomerulosclerosis Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- 206010019280 Heart failure Diseases 0.000 description 2
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010069384 Ischaemic nephropathy Diseases 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- 229940067606 Lecithin Drugs 0.000 description 2
- 206010025135 Lupus erythematosus Diseases 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 206010027525 Microalbuminuria Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010029149 Nephropathy Diseases 0.000 description 2
- 206010029151 Nephropathy Diseases 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N Perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- 206010065427 Reflux nephropathy Diseases 0.000 description 2
- 206010038378 Renal artery stenosis Diseases 0.000 description 2
- 206010038444 Renal failure chronic Diseases 0.000 description 2
- 206010038548 Renal vein thrombosis Diseases 0.000 description 2
- 206010039020 Rhabdomyolysis Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000010380 Tumor Lysis Syndrome Diseases 0.000 description 2
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 2
- 210000000626 Ureter Anatomy 0.000 description 2
- 210000003932 Urinary Bladder Anatomy 0.000 description 2
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 2
- 206010053648 Vascular occlusion Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000005418 aryl aryl group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000003143 atherosclerotic Effects 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N butylene glycol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 201000000522 chronic kidney disease Diseases 0.000 description 2
- 230000035512 clearance Effects 0.000 description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 201000004044 liver cirrhosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 2
- 229940039748 oxalate Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004450 types of analysis Methods 0.000 description 2
- 230000002485 urinary Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical compound C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- ILYBMUDLGFMEMU-UHFFFAOYSA-N 7-$l^{1}-oxidanyl-2,3,4,5,6,7-hexaoxoheptan-1-olate Chemical compound [O]C(=O)C(=O)C(=O)C(=O)C(=O)C(=O)C[O-] ILYBMUDLGFMEMU-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 210000002565 Arterioles Anatomy 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 208000001183 Brain Injury Diseases 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229940090805 Clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-Threitol Natural products OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 229940009714 Erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N Erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical group CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 210000003722 Extracellular Fluid Anatomy 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 Glyceryl Distearate Drugs 0.000 description 1
- 240000007842 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N Methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 description 1
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N Pyrophosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 210000002254 Renal Artery Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 230000037165 Serum Concentration Effects 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229950002757 Teoclate Drugs 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 1
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-α-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 1
- HDYANYHVCAPMJV-USQUEEHTSA-N Udp-Glucuronic Acid Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1[C@@H]([C@H]([C@@H](O1)N1C(NC(=O)C=C1)=O)O)O)[C@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HDYANYHVCAPMJV-USQUEEHTSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N Uridine Natural products O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- 229940045145 Uridine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N Xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 Xylitol Drugs 0.000 description 1
- NWGKJDSIEKMTRX-HSACVWGTSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (E)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-HSACVWGTSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 231100000494 adverse effect Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000001447 alkali salts Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000003126 anuria Diseases 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000004171 ischemic cascade Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002829 nitrogen Chemical group 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000002674 obstructive nephropathy Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrugs Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940005657 pyrophosphoric acid Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Abstract
The invention provides formulations containing a P2Y14 antagonist, such as the naphthoic acid derivative PPTN, and an agent that increases the solubility of the P2Y 14 antagonist in an aqueous medium. The invention also provides methods of using the formulations to treat kidney disorders and conditions associated with renal inflammation.
Description
PHARMACEUTICAL FORMULATIONS CONTAINING P2Y14 ANTAGONISTS
Cross-Reference to Related Applications
This application claims the benefit of, and priority to, U.S. Provisional Patent Application No. 62/834,517, filed April 16, 2019, the contents of which are incorporated by reference.
Field of the Invention
The invention relates generally to pharmaceutical formulations that contain P2Y 14 antagonists, such as naphthoic acid derivatives.
Background
Nephritis, or inflammation of the kidneys, is among the top ten causes of death for women in the United States. Inflammation of the kidneys impairs their ability to filter blood, so the blood accumulates metabolic waste products and loses essential components, either of which may be fatal. For example, the loss of factors that limit blood clotting may result in a stroke. Nephritis may be triggered by a variety of conditions, such as cardiac surgery, kidney
transplantation, infections, diabetes, hypertension, injuries, and autoimmune disorders such as lupus.
One compound that has shown promise as a therapeutic agent to limit renal inflammation is the naphthoic acid derivative 4-((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2- naphthoic acid (PPTN). PPTN functions by inhibiting the purinergic receptor P2Y 14, a key mediator of renal inflammation. However, PPTN is highly hydrophobic and has low water- solubility, so it has low bioavailability when administered to patients as a pharmacological agent. Efforts to overcome these problems by making chemical modifications of PPTN have failed because the altered compounds are inactive toward P2Y 14. Consequently, current treatments for nephritis are inadequate, and the condition continues to lead to death or serious medical problems for millions of people each year.
Summary
The invention provides pharmaceutical formulations containing solutions of P2Y14 antagonists, such as PPTN, at therapeutically useful concentrations. The formulations include a
non-toxic agent, such as sulfobutyl ether beta-cyclodextrin (SBECD) or a-tocopherol polyethylene glycol succinate (TPGS), that increases the solubility of naphthoic acid derivatives in aqueous solutions within a physiologically acceptable pH range, e.g., 5.0-8.0. Consequently, the formulations allow direct administration, e.g., by intravenous injection or infusion, of therapeutically effective quantities of naphthoic acid derivatives such as PPTN or other P2Y14 antagonists.
Because the formulations of the invention allow delivery of PPTN and other P2Y 14 antagonists at high levels, the formulations are useful for the treatment or prevention of renal inflammation. Thus, the invention also provides methods of treating or preventing renal inflammation in a subject using the formulations described herein.
In an aspect, the invention provides pharmaceutical formulations that contain a P2Y 14 antagonist and an agent.
The P2Y 14 antagonist may be a naphthoic acid derivative or salt thereof. The naphthoic acid derivative or salt thereof may be 4-((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)- phenyl)-2-naphthoic acid (PPTN). The salt of the naphthoic acid derivative may be PPTN hydrochloride. The P2Y 14 antagonist may be a triazole derivative.
The formulation may contain the P2Y 14 antagonist at a certain concentration. For example, the P2Y 14 antagonist may be present in the formulation at > 0.001 mg/ml, > 0.002 mg/ml, > 0.005 mg/ml, > 0.01 mg/ml, > 0.02 mg/ml, > 0.05 mg/ml, > 0.1 mg/ml, > 0.2 mg/ml, > 0.5 mg/ml, > 1 mg/ml, > 2 mg/ml, > 5 mg/ml, > 10 mg/ml, > 20 mg/ml, > 50 mg/ml, > 100 mg/ml, > 200 mg/ml, > 500 mg/ml, > 1 mg/ml, > 2 mg/ml, > 5 mg/ml, or > 10 mg/ml. The P2Y 14 antagonist may be present in the formulation at from about 1 mg/ml to about 20 mg/ml, from about 2 mg/ml to about 20 mg/ml, from about 5 mg/ml to about 20 mg/ml, from about 10 mg/ml to about 20 mg/ml, from about 20 mg/ml to about 20 mg/ml, from about 50 mg/ml to about 20 mg/ml, from about 100 mg/ml to about 20 mg/ml, from about 200 mg/ml to about 20 mg/ml, from about 500 mg/ml to about 20 mg/ml, from about 1 mg/ml to about 20 mg/ml, from about 2 mg/ml to about 20 mg/ml, from about 5 mg/ml to about 20 mg/ml, from about 1 mg/ml to about 10 mg/ml, from about 2 mg/ml to about 10 mg/ml, from about 5 mg/ml to about 10 mg/ml, from about 10 mg/ml to about 10 mg/ml, from about 20 mg/ml to about 10 mg/ml, from about 50 mg/ml to about 10 mg/ml, from about 100 mg/ml to about 10 mg/ml, from about 200 mg/ml to about 10 mg/ml, from about 500 mg/ml to about 10 mg/ml, from about 1 mg/ml to about 10
mg/ml, from about 2 mg/ml to about 10 mg/ml, from about 5 mg/ml to about 10 mg/ml, from about 1 mg/ml to about 5 mg/ml, from about 2 mg/ml to about 5 mg/ml, from about 5 mg/ml to about 5 mg/ml, from about 10 mg/ml to about 5 mg/ml, from about 20 mg/ml to about 5 mg/ml, from about 50 mg/ml to about 5 mg/ml, from about 100 mg/ml to about 5 mg/ml, from about 200 mg/ml to about 5 mg/ml, from about 500 mg/ml to about 5 mg/ml, from about 1 mg/ml to about 5 mg/ml, from about 2 mg/ml to about 5 mg/ml, from about 1 mg/ml to about 2 mg/ml, from about 2 mg/ml to about 2 mg/ml, from about 5 mg/ml to about 2 mg/ml, from about 10 mg/ml to about 2 mg/ml, from about 20 mg/ml to about 2 mg/ml, from about 50 mg/ml to about 2 mg/ml, from about 100 mg/ml to about 2 mg/ml, from about 200 mg/ml to about 2 mg/ml, from about 500 mg/ml to about 2 mg/ml, or from about 1 mg/ml to about 2 mg/ml.
The pharmaceutical formulation may be an aqueous solution.
The agent may increase to the solubility of the P2Y 14 antagonist in an aqueous solution. The agent may be a- tocopherol polyethylene glycol succinate (TPGS) or sulfobutyl ether beta- cyclodextrin (SBECD).
The formulation may contain the agent at a certain concentration. For example, the agent may be present in the formulation at less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 2%, less than about 1%, less than about 0.5%, less than about 0.2%, less than about 0.1%, less than about 0.05%, less than about 0.02%, less than about 0.01%, less than about 0.005%, less than about 0.002%, or less than about 0.001%. The agent may be present in the formulation at from about 0.001% to about 0.01%, from about 0.003% to about 0.03%, from about 0.01% to about 0.1%, from about 0.03% to about 0.03%, from about 0.1% to about 1%, from about 0.3% to about 3%, from about 1% to about 10%, from about 2% to about 10%, from about 3% to about 10%, from about 5% to about 10%, from about 5% to about 12%, from about 5% to about 15%, from about 5% to about 20%, from about 7.5% to about 10%, from about 7.5% to about 12%, from about 7.5% to about 15%, from about 7.5% to about 20%, from about 10% to about 12%, from about 10% to about 15%, or from about 10% to about 20%.
The formulation may have a pH in a physiologically-compatible range. The formulation may have a pH of > 4.0, > 4.5, > 5.0, > 5.5, > 6.0, > 6.5, > 7.0, > 7.5, or > 8.0. The formulation may have a pH within a range. For example, the formulation may have a pH of from about 4.0 to about 9.0, from about 5.0 to about 9.0, from about 6.0 to about 9.0, from about 7.0 to about
9.0, from about 4.0 to about 8.0, from about 5.0 to about 8.0, from about 6.0 to about 8.0, from about 7.0 to about 8.0, from about 4.0 to about 7.0, from about 5.0 to about 7.0, or from about 6.0 to about 7.0. The formulation may have a pH of about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, or about 8.0.
The formulation may contain a buffering agent and/or one or more salts. The buffering agent may be phosphate. The salt may be sodium chloride or potassium chloride. The formulation may contain saline or phosphate-buffered saline.
The formulation may contain dimethyl sulfoxide (DMSO). DMSO may be present in the formulation at less than about 10%, less than about 5%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5%, less than about 0.3%, less than about 0.2%, or less than about 0.1%.
The formulation may be substantially free of solvents or other chemicals that may be toxic to a subject. For example, the formulation may be substantially free of dimethylacetamide (DMAc), ethanol, N-methylpyrrolidone (NMP), and/or polyethylene glycol (PEG).
In another aspect, the invention provides methods of treating a renal disorder by providing to a subject a formulation containing a P2Y 14 antagonist and an agent.
The renal disorder may be any disease, disorder, or condition associated with renal inflammation. The renal disorder or condition associated with renal inflammation may be accumulation of mesangial matrix, acute interstitial nephritis, acute kidney injury (AKI), including AKI associated with cardiac surgery, acute tubular necrosis (ATN), Alport syndrome, atherosclerosis, atherosclerotic renal artery stenosis, an autoimmune disorder, such us systemic lupus erythematosus, autosomal dominant polycystic kidney disease (ADPKD), benign prostatic hyperplasia, bladder stones, cancer, including cancer of the bladder, ureters, or prostate, cardiac surgery, cell apoptosis, chronic kidney disease, chronic tubulointerstitial nephritis, delayed graft function (DGF), including DGF-renal, diabetes, diabetic nephropathy, including type 1 diabetic nephropathy (T1D nephropathy), end-stage renal disease, Focal segmental glomerulosclerosis (FSGS), glomerular basement membrane thickening, glomerular hyperfiltration, glomerular and tubular epithelial hypertrophy, glomerulonephritis, glomerulosclerosis, heart failure, hemolytic- uremic syndrome, hypertension, IgA nephropathy (also called Berger's disease), infection, injury, ischemia, ischemia/reperfusion injury, ischemic nephropathy, kidney hypoxia, kidney stones, kidney transplantation, liver cirrhosis, methyl melonic acidosis (MMA), microalbuminuria,
obstructed urinary catheter, proteinuria, reduced creatinine clearance, reduced glomerular filtration rate, reflux nephropathy, renal vein thrombosis, rhabdomyolysis, tumor lysis syndrome, vascular occlusion, or vasculitis.
The formulation may have any of the properties described above in relation to
formulations of the invention. For example, the P2Y 14 antagonist may be a naphthoic acid derivative or salt thereof, and the agent may be SBECD or TPGS.
Brief Description of the Drawings
FIG. 1 is graph showing HPLC analysis of a single concentration of PPTN.
FIG. 2 is graph showing HPLC analysis of different concentrations of PPTN.
FIG. 3 is a graph of UV absorption at 268 nm vs. concentration of PPTN.
FIG. 4 is graph showing the concentration of PPTN in saturated solutions that contain different amounts of SBECD.
FIG. 5 is a graph of PPTN concentrations of samples tested in stability assay.
FIG. 6 is a representative UHPLC-UV trace for the sample at 40°C, time = 28 days.
FIG. 7 is a graph of plasma PPTN concentration over time in rats after a single bolus injection.
FIG. 8 is a graph of plasma PPTN concentration as a function of dose in rats after a single bolus injection.
FIG. 9 is a graph of urine PPTN concentration over time in rats after a single bolus injection.
FIG. 10 is a graph of plasma PPTN concentration over time in rats during continuous intravenous administration for 24 hours.
FIG. 11 is a graph of plasma PPTN concentration over time in rats during continuous intravenous administration for 72 hours.
FIG. 12 is a graph of plasma PPTN concentration as a function of dose in rats during continuous intravenous infusion.
FIG. 13 is a standard curve of plasma PPTN concentrations from rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours.
FIG. 14 is a standard curve of plasma PPTN concentrations from rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours.
FIG. 15 is a standard curve of plasma PPTN concentrations from rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours.
FIG. 16 is a standard curve of urine PPTN concentrations from rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours.
FIG. 17 is a standard curve of urine PPTN concentrations from rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours.
FIG. 18 is a standard curve of urine PPTN concentrations from rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours.
FIG. 19 is a standard curve of a summary of urine concentrations of PPTN in rats that received continuous intravenous infusion for 24 or 72 hours.
Detailed Description
Renal inflammation, or nephritis, is potentially life-threating condition associated with a wide range of diseases, disorders, and conditions. For example, renal inflammation may result from cardiac surgery, kidney transplantation, infections, diabetes, hypertension, injuries, and autoimmune disorders, such as lupus. Inflammation impairs the kidneys' ability to filter blood, resulting in the accumulation of waste products and the loss of vital blood components.
Recent reports have identified the purinergic receptor P2Y 14, also called GPR105, as a key mediator of renal inflammation. The gene and protein for human P2Y 14 are described in, for example, Entrez Gene ID no. 9934, GenBank ID no. D13626, RefSeq ID no. NM_014879, and UniProt ID no. NM_01487, the contents of which are incorporated herein by reference.
P2Y 14 is a G protein-coupled receptor expressed on the surface of intercalated cells (ICs) in the collecting duct system of the kidney. P2Y 14 binds uridine diphosphate glucose (UDP-glucose), an ester of pyrophosphoric acid with the nucleoside uridine, and related UDP-hexoses, such as UDP-galactose, UDP-glucuronic acid, N-acetyl-UDP-glucosamine and N-acetyl-UDP- galactosamine. Abbracchio et ah, Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family, Trends Pharmacol Sci. 2003 Feb;24(2):52-5, DOI: 10.1016/S0165-6147(02)00038-X, the contents of which are incorporated herein by reference. These hexoses are agonists for the P2Y 14 receptor, and throughout this text, "UDP-glucose" and "UDP-glucose and related UDP-hexoses" refer to this group of hexoses unless otherwise expressly indicated that only UDP-glucose is intended. UDP-glucose and
related UDP-hexoses are released into extracellular fluids from damaged cells and in a regulated manner from intact cells. Binding of UDP-glucose to P2Y 14 triggers ICs to produce chemokines that lead to infiltration of neutrophils into the renal medulla. See Azroyan et al., Renal
Intercalated Cells Sense and Mediate Inflammation via the P2Y14 Receptor, PLoS ONE 10(3): e0121419 (2015), doi:10.1371/journal.pone.0121419. Thus, high levels of circulating UDP- glucose activate P2Y 14 to cause renal inflammation.
The naphthoic acid derivative 4-((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)- phenyl)-2-naphthoic acid (PPTN) has been identified as an antagonist of P2Y 14. However, PPTN is highly hydrophobic, which presents challenges in developing formulations that deliver PPTN at levels sufficient to combat renal inflammation. Prior formulations of PPTN have poor bioavailability. The solubility of PPTN is increased under acidic conditions, but highly acidic solutions disrupt the pH of the blood when administered intravenously and thus are not suitable for therapeutic use. In addition, efforts to modify the molecule to increase its water- solubility have failed because the PPTN derivatives are poor antagonists of P2Y 14.
The invention overcomes the aforementioned problems by providing formulations that contain P2Y14 antagonists, including naphthoic acid derivatives such as PPTN, at concentrations sufficient to provide therapeutic benefit. The formulations include one or more agents, such as sulfobutyl ether beta-cyclodextrin (SBECD) and a-tocopherol polyethylene glycol succinate (TPGS), that increase the solubility of PPTN and similar compounds at near-neutral pH.
Consequently, the formulations allow delivery of high levels of P2Y14 antagonists to treat renal inflammation without disrupting the body's homeostatic processes.
Formulations
P2Y14 antagonists
The invention provides formulations that contain P2Y 14 antagonists. The P2Y 14 antagonist may be any entity that interferes with ligand-binding, activation, or signaling by P2Y 14. The P2Y 14 antagonist may be a small or large organic or inorganic molecule.
The P2Y 14 antagonist may be a 4,7-disubstituted naphthoic acid derivative, such as one of the compounds described in U.S. Publication No. 2010/0298347, the contents of which are incorporated herein by reference. Such compounds may be represented by formula (I):
R1 is selected from the group consisting of hydrogen, C3-6 cycloalkyl, benzyl, and C1_6 alkyl wherein alkyl is optionally substituted with hydroxy, amino, C1-4 alkylamino, di-(C1_4 alkyl)amino, aminocarbonyl, C1-4 alkylaminocarbonyl, di-(C1_4alkyl)aminocarbonyl, C1-4 alkylcarbonyloxy, C1_4 alkyloxy, or one to five fluorines;
R is hydrogen, fluorine, or hydroxy;
a
R is selected from the group consisting of:— (CH2),»aryl,— (CH2)mheteroaryl,— OCH2- aryl,— OCH2-heteroaryl,— (S)rCH2-aryl,— (S)rCH2-heteroaryl,— CH20-aryl,— CH2O- heteroaryl,— CH2(S)r-aryl, and— CH2(S)r-heteroaryl;
wherein any methylene (CH2) carbon atom in R3 is optionally substituted with one to two groups independently selected from fluorine, hydroxy, and C1_4 alkyl optionally substituted with one to three fluorines; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group; and wherein aryl and heteroaryl are optionally substituted with one to three Rc substituents independently selected from the group consisting of:
halogen,
cyano,
nitro,
C1-6 alkoxy, wherein alkoxy is optionally substituted with one to five substituents independently selected from fluorine, hydroxy, and C1-3 alkoxy,
C1-6 alkyl, wherein alkyl is optionally substituted with one to five substituents independently selected from fluorine, hydroxy, and C1_3 alkoxy,
C2-6 alkenyl, wherein alkenyl is optionally substituted with one to five substituents independently selected from fluorine, hydroxy, and C1-3 alkoxy,
(CH2)„-aryl,
(CH2)„-hctciOaryl,
(CH2)„-hctciOcyclyl,
(CH2)„— C3-6 cycloalkyl,
(CH2)„— OR9,
(CH2)„— CO2R9,
(CH2)„- N(R9)2,
(CH2)„- CON(R9)2,
(CH2)„— OCON(R9)2,
(CH2)„— S02N(R9)2,
(CH2)„- S02N(R9)C(0)R9,
(CH2)„— C(0)„(R9)S02R10,
(CH2)„— S(0)rR10,
(CH2)„— NR11 S 02R10 ;
(CH2)„- NRnCON(R9)2,
(CH2)„— NRnCOR9, and
(CH2)„— NRnC02R10;
wherein aryl, heteroaryl, cycloalkyl, and heterocyclyl are optionally substituted with one to three substituents independently selected from halogen, hydroxy, C1_4 alkyl, trifluoromethyl, and C1_4 alkoxy; and wherein any methylene (CH2) carbon atom in Rc is optionally substituted with one to two groups independently selected from fluorine, hydroxy, and C1-4 alkyl optionally substituted with one to three fluorines; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
R , R , R , and R are each independently selected from the group consisting of:
hydrogen,
halogen,
C1_4 alkyl, optionally substituted with one to five fluorines,
C1_4 alkoxy, optionally substituted with one to five fluorines, and
C1_4 alkylthio, optionally substituted with one to five fluorines;
R6 is selected from the group consisting of:
— (CH2)m-aryl,
— (CH2)m-heteroaryl,
— OCH2-aryl,
— OCH2-heteroaryl,
— (S)rCH2-aryl,
— (S)rCH2-heteroaryl,
— CH20-aryl,
— CH20-heteroaryl,
— CH2(S)r-aryl, and
— CH2(S ) ,-heteroaryl ;
wherein any methylene (CH2) carbon atom in R6 is optionally substituted with one to two groups independently selected from fluorine, hydroxy, and C1_4 alkyl optionally substituted with one to three fluorines; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group and wherein aryl and heteroaryl are optionally substituted with one to three Rd substituents independently selected from the group consisting of:
halogen,
cyano,
C1_4 alkyl, optionally substituted with one to five fluorines,
C1_4 alkoxy, optionally substituted with one to five fluorines,
C1_4 alkylthio, optionally substituted with one to five fluorines, and
C1_4 alkylsulfonyl, optionally substituted with one to five fluorines;
each R9 is independently selected from the group consisting of hydrogen,
C1-6 alkyl,
(CH2)m-aryl,
(CH2)m-heteroaryl, and
(CH2)mC3-6 cycloalkyl;
wherein any individual methylene (CH2) carbon atom in (CH2)m is optionally substituted with one to two substituents independently selected from fluorine, hydroxy, C1_4 alkyl, and C1_4 alkoxy, wherein alkyl and alkoxy are optionally substituted with one to five fluorines; or two substituents when on the same methylene (CH2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group; and wherein alkyl, aryl, heteroaryl, and
cycloalkyl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C1-4 alkyl, and C1-4 alkoxy; or two R9 groups substituents together with the nitrogen atom to which they are attached form a heterocyclic ring selected from azetidine, pyrrolidine, piperidine, piperazine, and morpholine wherein said heterocyclic ring is optionally substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, C1-6alkyl, and C1-6 alkoxy, wherein alkyl and alkoxy are optionally substituted with one to five fluorines;
each R10 is independently C1-6 alkyl, wherein alkyl is optionally substituted with one to five substituents independently selected from fluorine and hydroxy;
R11 is hydrogen or R10;
each n is independently an integer from 0 to 3;
each m is independently an integer from 0 to 2; and
each r is an integer from 0 to 2.
The naphthoic acid derivative may be 4-[4-(piperidin-4-yl)phenyl]-7-[4- (trifluoromethyl)phenyl] -2-naphthoic acid (PPTN), which has the following structure:
The P2Y 14 antagonist may be a triazole derivative, such as one of the compounds described in WO 2017/053769, the contents of which are incorporated herein by reference. Such compounds may be represented by the formula (XI):
wherein
ring A is aryl, heteroaryl, or cycloalkyl;
R1 is -CO2H, -C02(Ci-Cg alkyl), or a bioisostere of carboxylate;
R2 is H, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6
cycloalkylalkyl, hydroxyalkyl, Ci-Cs haloalkyl, cyanoalkyl, aryl, heteroaryl, heterocycloalkyl, -(CH2)maryl, -(CH2)mheteroaryl, or -(CH2)mheterocycloalkyl;
a
each R is the same or different and each is Ci-Cs alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, hydroxy, hydroxyalkyl, Ci-Cs alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, Ci-Cs haloalkyl, Ci- C8 haloalkoxy, -CN, -N02, -NR5R6, -C(0)R4, -C02R4, -C(0)NR5R6, -NR5C(0)R4,
-(CFkjniaryl, -(CH2)mheteroaryl, or -(CH2)mheterocycloalkyl;
R4, R5, and R6 are the same or different and each is H or Ci-Cs alkyl; and
m and n are the same or different and each is 0 or an integer from 1-5;
or a pharmaceutically acceptable salt thereof.
Other compounds described in WO 2017/053769 that may be used as P2Y 14 antagonists are represented by the formula (XII):
ring A' is aryl, heteroaryl, or cycloalkyl;
R is -CO2H, -C02(Ci-Cg alkyl), or a bioisostere of carboxylate;
R2 is H, Ci-Cg alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C6 cycloalkyl, C3-C6
cycloalkylalkyl, hydroxy alkyl, Ci-Cs haloalkyl, cyanoalkyl, aryl, heteroaryl,
heterocycloalkyl, -(CH2)maryl, -(CH2)mheteroaryl, or -(CH2)mheterocycloalkyl;
each R is the same or different and each is Ci-Cs alkyl, C2-C8 alkenyl, C3-C6 cycloalkyl, hydroxy, hydroxyalkyl, Ci-Cs alkoxy, C3-C6 cycloalkyloxy, aryloxy, halo, Ci-Cs haloalkyl, Ci- C8 haloalkoxy, -CN, -N02, -NR5R6', -C(0)R4, -C02R4, -C(0)NR5R6', -NR5'C(0)R4',
-(CH2)maryl, -(CH2)mheteroaryl, or -(CH2)mheterocycloalkyl;
R4 , R5 , and R6 are the same or different and each is H or Ci-Cs alkyl; and
m' and n' are the same or different and each is 0 or an integer from 1-5;
or a pharmaceutically acceptable salt thereof.
The P2Y 14 antagonist may be a prodrug, analog, derivative, or pharmaceutically acceptable salt of PPTN or of any other active compound that inhibits P2Y 14.
Any of the compounds described above may be provided as a pharmaceutically acceptable salt. For example and without limitation, the pharmaceutically acceptable salt may include one or more of 2-hydroxy-ethanesulfonate, 2-naphthalenesulfonate, 3-phenylpropionate, acetate, adipate, alginate, andvalerate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, clavulanate, cyclopentanepropionate, digluconate, dihydrochloride, diphosphate, dodecylsulfate, edetate, edisylate, estolate, esylate,
ethanesulfonate, formate, fumarate, gluceptate, glucoheptonate, gluconate, glutamate, glycerophosphate, glycollylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methanesulfonate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nicotinate, nitrate, N-methylglucamineammoniumsalt, oleate, oleate, oxalate, oxalate, palmitate, pamoate (embonate), pantothenate, pectinate, persulfate, phosphate, picrate, pivalate, polygalacturonate, propionate, p-toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, tamiate, tartrate, teoclate, thiocyanate, tosylate, triethiodide, undecanoate, and valerate. Other pharmaceutically acceptable salts include nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, a pharmaceutically acceptable salt is an alkali salt. In some embodiments, a pharmaceutically acceptable salt is a sodium salt. In some embodiments, a pharmaceutically acceptable salt is an alkaline earth metal salt. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counter ions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
Agents that increase solubility of P2Y 14 antagonists
The formulations of the invention include one or more agents that increase the solubility of a P2Y14 antagonist, such as PPTN, in an aqueous medium. Examples of suitable agents include sulfobutyl ether beta-cyclodextrin (SBECD) or a-tocopherol polyethylene glycol succinate (TPGS).
The presence of the agent may allow the formulation to contain a certain concentration of the P2Y 14 antagonist. Thus, the formulation, including the P2Y 14 antagonist and the agent, may contain the P2Y14 antagonist at > 0.001 mg/ml, > 0.002 mg/ml, > 0.005 mg/ml, > 0.01 mg/ml, > 0.02 mg/ml, > 0.05 mg/ml, > 0.1 mg/ml, > 0.2 mg/ml, > 0.5 mg/ml, > 1 mg/ml, > 2 mg/ml, > 5 mg/ml, > 10 mg/ml, > 20 mg/ml, > 50 mg/ml, > 100 mg/ml, > 200 mg/ml, > 500 mg/ml, > 1
mg/ml, > 2 mg/ml, > 5 mg/ml, > 10 mg/ml, from about 1 mg/ml to about 20 mg/ml, from about 2 mg/ml to about 20 mg/ml, from about 5 mg/ml to about 20 mg/ml, from about 10 mg/ml to about 20 mg/ml, from about 20 mg/ml to about 20 mg/ml, from about 50 mg/ml to about 20 mg/ml, from about 100 mg/ml to about 20 mg/ml, from about 200 mg/ml to about 20 mg/ml, from about 500 mg/ml to about 20 mg/ml, from about 1 mg/ml to about 20 mg/ml, from about 2 mg/ml to about 20 mg/ml, from about 5 mg/ml to about 20 mg/ml, from about 1 mg/ml to about 10 mg/ml, from about 2 mg/ml to about 10 mg/ml, from about 5 mg/ml to about 10 mg/ml, from about 10 mg/ml to about 10 mg/ml, from about 20 mg/ml to about 10 mg/ml, from about 50 mg/ml to about 10 mg/ml, from about 100 mg/ml to about 10 mg/ml, from about 200 mg/ml to about 10 mg/ml, from about 500 mg/ml to about 10 mg/ml, from about 1 mg/ml to about 10 mg/ml, from about 2 mg/ml to about 10 mg/ml, from about 5 mg/ml to about 10 mg/ml, from about 1 mg/ml to about 5 mg/ml, from about 2 mg/ml to about 5 mg/ml, from about 5 mg/ml to about 5 mg/ml, from about 10 mg/ml to about 5 mg/ml, from about 20 mg/ml to about 5 mg/ml, from about 50 mg/ml to about 5 mg/ml, from about 100 mg/ml to about 5 mg/ml, from about 200 mg/ml to about 5 mg/ml, from about 500 mg/ml to about 5 mg/ml, from about 1 mg/ml to about 5 mg/ml, from about 2 mg/ml to about 5 mg/ml, from about 1 mg/ml to about 2 mg/ml, from about 2 mg/ml to about 2 mg/ml, from about 5 mg/ml to about 2 mg/ml, from about 10 mg/ml to about 2 mg/ml, from about 20 mg/ml to about 2 mg/ml, from about 50 mg/ml to about 2 mg/ml, from about 100 mg/ml to about 2 mg/ml, from about 200 mg/ml to about 2 mg/ml, from about 500 mg/ml to about 2 mg/ml, or from about 1 mg/ml to about 2 mg/ml.
The agent may promote solubility of the P2Y 14 antagonist at a near-neutral pH. Thus, the formulation, including the P2Y 14 antagonist and the agent, may have a pH of > 4.0, > 4.5, > 5.0, > 5.5, > 6.0, > 6.5, > 7.0, > 7.5, > 8.0, from about 4.0 to about 9.0, from about 5.0 to about 9.0, from about 6.0 to about 9.0, from about 7.0 to about 9.0, from about 4.0 to about 8.0, from about 5.0 to about 8.0, from about 6.0 to about 8.0, from about 7.0 to about 8.0, from about 4.0 to about 7.0, from about 5.0 to about 7.0, from about 6.0 to about 7.0, about 5.0, about 5.5, about 6.0, about 6.5, about 7.0, about 7.5, or about 8.0.
The agent may be present in the formulation at a certain concentration. For example, the agent may be present in the formulation at less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 2%, less than about 1%, less than about 0.5%, less than about
0.2%, less than about 0.1%, less than about 0.05%, less than about 0.02%, less than about 0.01%, less than about 0.005%, less than about 0.002%, less than about 0.001%, from about 0.001% to about 0.01%, from about 0.003% to about 0.03%, from about 0.01% to about 0.1%, from about 0.03% to about 0.3%, from about 0.1% to about 1%, from about 0.3% to about 3%, from about 1% to about 10%, from about 2% to about 10%, from about 3% to about 10%, from about 5% to about 10%, from about 5% to about 12%, from about 5% to about 15%, from about 5% to about 20%, from about 7.5% to about 10%, from about 7.5% to about 12%, from about 7.5% to about 15%, from about 7.5% to about 20%, from about 10% to about 12%, from about 10% to about 15%, or from about 10% to about 20%.
The agent may improve the stability of the P2Y 14 antagonist. For example, the agent may increase the half-life of the P2Y 14 antagonist by about 10%, about 25%, about 50%, about 100%, about 200%, about 500%, about 1000%, or more.
Other properties of formulations
The formulations of the inventions may contain additional ingredients.
The formulation may contain salts and/or buffering agents. The buffering agent may be phosphate. The salt may be sodium chloride or potassium chloride. The formulation may contain saline or phosphate-buffered saline. Other salts and buffering agents are described in more detail below.
The formulation may contain dimethyl sulfoxide (DMSO). The formulation may contain DMSO at or below a certain concentration. For example, DMSO may be present in the formulation at less than about 10%, less than about 5%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5%, less than about 0.3%, less than about 0.2%, or less than about 0.1%.
The formulation may be substantially free of solvents or other chemicals that are not suitable for administration to a subject. For example, the formulation may be substantially free of dimethylacetamide (DMAc), ethanol, N-methylpyrrolidone (NMP), and/or polyethylene glycol (PEG).
The formulation may be a pharmaceutical composition. A pharmaceutical composition may be in a form suitable for oral use, for example, as tablets, troches, lozenges, fast-melts, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs. Compositions intended for oral use may be prepared according to any method
known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the compounds in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as lactose; granulating and disintegrating agents, for example com starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
The tablets may be uncoated or they may be coated by known techniques to delay disintegration in the stomach and absorption lower down in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patents 4,256,108, 4,166,452 and 4,265,874, to form osmotic therapeutic tablets for control release. Preparation and administration of compounds is discussed in U.S. Pat. 6,214,841 and U.S. Pub. 2003/0232877, which are incorporated by reference herein in their entirety.
Formulations for oral use may also be presented as hard gelatin capsules in which the compounds are mixed with an inert solid diluent, such as kaolin. The formulations may be presented as soft gelatin capsules in which the compounds are mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
An alternative oral formulation, where control of gastrointestinal tract hydrolysis of the compound is sought, can be achieved using a controlled-release formulation, where a compound of the invention is encapsulated in an enteric coating.
Aqueous suspensions may contain the compounds in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents such as a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example, polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a
hexitol such a polyoxyethylene with partial esters derived from fatty acids and hexitol anhydrides, for example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the compounds in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the compounds in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, such as glycerol, propylene glycol, sorbitol, or sucrose. Such formulations may also contain a demulcent, a preservative, and agents for flavoring and/or coloring. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be in a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or
solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
The pharmaceutical composition may be formulated for intravenous injection or infusion or subcutaneous administration. For example, the compositions may be dissolved, suspended or emulsified. The compositions may also be lyophilized, and the lyophilized material may be used to prepare a formulation for injection. Suitable solvents for injectable formulations include, for example and without limitation, water, physiological saline solution, alcohols, e.g. ethanol, propanol, glycerol, sugar solutions, such as hexose or mannitol solutions, and mixtures of the aforementioned solvents. The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic monoglycerides or diglycerides, and fatty acids, including oleic acid.
The pharmaceutical composition may be formulated for delivery of a compound that is insoluble or poorly soluble in water. Examples of such formulations include nanoparticles, microparticles, nanosuspensions, phospholipid-coated microcrystals, emulsions, and stable aqueous formulations. Formulations for delivery of insoluble or poorly soluble compounds are known in the art and described in, for example, U.S. Patent No. 5,091,187; U.S. Patent No. 5,858,410; U.S. Patent No. 8,313,777; U.S. Patent No. 9,308,180; U.S. Publication No.
2002/0012704; U.S. Publication No. 2003/0027858; U.S. Publication No. 2008/0166411; U.S. Publication No. 2010/0093872; U.S. Publication No. 2013/0115165; International Publication No. WO 2014/165660; Pace S. et ah,“Novel injectable formulations of insoluble drugs”, Pharm. Tech, 1999, 23:116-134; and Panagiotou T. et ah,“Production of stable nanosuspensions using microfluidics reaction technology”, Nanotech. 2007, 4:246-249, ISBN 1420063766, the contents of each of which are incorporated herein by reference.
Pharmaceutical compositions may include other pharmaceutically acceptable carriers, such as sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose
and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin (glycerol), erythritol, xylitol. sorbitol, mannitol and polyethylene glycol; esters, such asethyl oleate and ethyllaurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and/or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.
Methods of treating renal disorders
Renal disorders and disorders associated with renal inflammation
The invention provides methods of treating kidney disorders or conditions associated with renal inflammation by providing to a subject a formulation of the invention. The methods are useful for treating any disease, disorder, or condition that is associated with renal
inflammation or for which treating or preventing renal inflammation provides a therapeutic benefit. The use of P2Y 14 antagonists to treat kidney disorders or conditions associated with renal inflammation is known in the art and described in, for example, U.S. Patent No. 9,891 236; International Patent Publication No. WO 2017/165665; and co-owned, co-pending U.S.
Application Nos. 62/658,241; 62/659,438; 62/662,932; 62/664,464; 62/675,256; 62/682,270, the contents of each of which are incorporate herein. Thus, the formulations of the invention may be used to treat any disease, disorder, or condition described in the foregoing patent applications.
For example and without limitation, the disease, disorder, or condition may be or include accumulation of mesangial matrix, acute interstitial nephritis, acute kidney injury (AKI), including AKI associated with cardiac surgery, acute tubular necrosis (ATN), Alport syndrome, atherosclerosis, atherosclerotic renal artery stenosis, an autoimmune disorder, such us systemic lupus erythematosus, autosomal dominant polycystic kidney disease (ADPKD), benign prostatic hyperplasia, bladder stones, cancer, including cancer of the bladder, ureters, or prostate, cardiac surgery, cell apoptosis, chronic kidney disease, chronic tubulointerstitial nephritis, delayed graft function (DGF), including DGF-renal, diabetes, diabetic nephropathy, including type 1 diabetic nephropathy (T1D nephropathy), end-stage renal disease, Focal segmental glomerulosclerosis (FSGS), glomerular basement membrane thickening, glomerular hyperfiltration, glomerular and
tubular epithelial hypertrophy, glomerulonephritis, glomerulosclerosis, heart failure, hemolytic- uremic syndrome, hypertension, IgA nephropathy (also called Berger's disease), infection, injury, ischemia, ischemia/reperfusion injury, ischemic nephropathy, kidney hypoxia, kidney stones, kidney transplantation, liver cirrhosis, methyl melonic acidosis (MMA), microalbuminuria, obstructed urinary catheter, proteinuria, reduced creatinine clearance, reduced glomerular filtration rate, reflux nephropathy, renal vein thrombosis, rhabdomyolysis, tumor lysis syndrome, vascular occlusion, or vasculitis.
The methods may treat or prevent renal inflammation associated with acute kidney injury (AKI). AKI may be assessed by any suitable standard. Several standards for acute kidney injury are known in the art, such as the criteria provided by the Acute Kidney Injury Network (AKIN); Kidney Disease Improving Global Outcomes (KDIGO); and Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE). AKI may be categorized or staged according to the AKI, KDIGO, or RIFLE criteria. For example, a subject may be deemed to have stage 1, stage 2, or stage 3 AKI, or a subject may be deemed to have risk, injury, failure, or loss. The standard may apply to an adult, pediatric, newborn, neonatal, infant, child, adolescent, pre-teen, teenage, or elderly subject.
Standards typically include measurements of serum creatinine (SCr) concentrations, urine output, or glomerular filtration rate (GFR). Standards may include multiple parameters, e.g., combinations of the aforementioned standards. A subject may be deemed to have AKI, or a stage or category thereof, when she has abnormally high SCr concentration, abnormally low urine output, abnormally low GFR, or any combination thereof. Standards may be absolute, e.g., they may require a value above or below a defined threshold value. Alternatively, standards may be relative, e.g., they may require an increase or decrease relative to a baseline value. Standards for different parameters, e.g., abnormally high SCr concentration abnormally low urine output, or abnormally low GFR, may independently be absolute or relative.
Standards for acute kidney injury may include a temporal component. For example, a subject may be deemed to have AKI when an elevated SCr concentration is measured at some interval following a preceding event. The preceding event may be cardiac surgery, cardiac arrest, admission to a hospital, clinic, medical facility, or any unit thereof. The interval may be 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, or 72 hours. A
subject may be deemed to have AKI when urine output is measured across some interval, such as 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, or 72 hours.
For example and without limitation, a standard for reduced urine output associated with AKI may be less than 0.5 mL/kg/h for 6-12 hours, less than 0.5 mL/kg/h for at least 12 hours, or less than 0.3 mL/kg/h for 24 hours, or anuria for at least 12 hours.
For example and without limitation, a standard for elevated SCr concentration associated with AKI may be a SCr concentration of at least 0.3 mg/dl, a SCr concentration of at least 1 mg/dl, a SCr concentration of at least 4 mg/dl, a SCr concentration of at least 26.5 pmol/l, or a SCr concentration of at least 353.6 pmol/l. For example and without limitation, a standard for elevated SCr concentration associated with AKI may be an increase of 50% over baseline, an increase of 100% over baseline, or an increase of 200% over baseline.
For example and without limitation, a standard for GFR associated with AKI may be a GFR of less than 35 ml/min per 1.73 mm . For example and without limitation, a standard for GFR associated with AKI may be a decrease of at least at least 25% relative to a baseline, a decrease of at least at least 50% relative to a baseline, or a decrease of at least at least 75% relative to a baseline.
The methods may treat or prevent renal inflammation associated with reperfusion injury. Reperfusion injury, which is also called reperfusion insult, ischemia-reperfusion injury, and reoxygenation injury, is the tissue damage that results when blood supply to the tissue is restored after a period of ischemia or lack of oxygen. The sudden influx of nutrients and oxygen after a bout of ischemia, anoxia, or hypoxia produces a high level of reactive oxygen species that exceeds the tissue's detoxification capacity. The oxidative stress is associated with
microvascular injury due to increased permeability of capillaries and arterioles that allows fluid to penetrate the tissue more readily. In addition, white blood cells in the returning blood respond to damaged tissue by releasing inflammatory factors.
Reperfusion injury can occur following any surgery that limits blood supply to an organ. In particular, reperfusion injury is a risk following cardiac procedures due to changes in blood during the procedure. Reperfusion injury is also a major concern in organ transplantation procedures due to the lack of blood flow to the organ while it is being transported.
Certain organs are particularly vulnerable to reperfusion injury. For example, reperfusion injury contributes to the brain's ischemic cascade in stroke or brain trauma, and also plays a role
in brain damage following cardiac arrest. The heart, kidneys, lungs, and liver may also be affected by reperfusion injury.
Without wishing to be bound by a particular theory, P2Y 14 antagonists may prevent or minimize reperfusion injury by preserving microvascular integrity. Therefore, it may be advantageous to provide a P2Y14 antagonist, such as any of the P2Y14 antagonists described above, to a patient before the patient undergoes a surgery that is likely to cause reperfusion injury. The surgery may be a cardiac procedure, such as any of the cardiac procedures described above. The P2Y 14 antagonist may be provided by any mechanism described above.
Methods of providing formulations
Providing the formulation to the subject may include administering it to the subject. The formulation may be administered by any suitable means. For example and without limitation, the formulation may be administered buccally, by injection or infusion, dermally, enterally, enterally, intraarterially, intravenously, nasally, orally, parenterally, pulmonarily, rectally, subcutaneously, topically, transdermally, vaginally, or with or on an implantable medical device (e.g. stent or drug-eluting stent or balloon equivalents). The formulation may be provided directly to the kidney via in vitro perfusion of the renal artery.
The P2Y 14 antagonist may be provided at any suitable dosage. For example and without limitation, the P2Y 14 antagonist may be provided at from 0.001 mg/kg body weight to 5 g/kg body weight. In some embodiments, the dosage range is from 0.001 mg/kg body weight to 1 g/kg body weight, from 0.001 mg/kg body weight to 0.5 g/kg body weight, from 0.001 mg/kg body weight to 0.1 g/kg body weight, from 0.001 mg/kg body weight to 50 mg/kg body weight, from 0.001 mg/kg body weight to 25 mg/kg body weight, from 0.001 mg/kg body weight to 10 mg/kg body weight, from 0.001 mg/kg body weight to 5 mg/kg body weight, from 0.001 mg/kg body weight to 1 mg/kg body weight, from 0.001 mg/kg body weight to 0.1 mg/kg body weight, or from 0.001 mg/kg body weight to 0.005 mg/kg body weight. Alternatively, in some
embodiments the dosage range is from 0.1 g/kg body weight to 5 g/kg body weight, from 0.5 g/kg body weight to 5 g/kg body weight, from 1 g/kg body weight to 5 g/kg body weight, from 1.5 g/kg body weight to 5 g/kg body weight, from 2 g/kg body weight to 5 g/kg body weight, from 2.5 g/kg body weight to 5 g/kg body weight, from 3 g/kg body weight to 5 g/kg body weight, from 3.5 g/kg body weight to 5 g/kg body weight, from 4 g/kg body weight to 5 g/kg body weight, or from 4.5 g/kg body weight to 5 g/kg body weight. These doses may be
administered at a single time or multiple times each day, or may be administered continuously, for example by continuous intravenous infusion. For example and without limitation, the P2Y 14 antagonist may be provided at from 0.001 mg/kg body weight/day (mg/kg/day) to 5 g/kg body weight/day. In some embodiments, the dosage range is from 0.001 mg/kg body weight/day to 1 g/kg body weight/day, from 0.001 mg/kg body weight/day to 0.5 g/kg body weight/day, from 0.001 mg/kg body weight/day to 0.1 g/kg body weight/day, from 0.001 mg/kg body weight/day to 50 mg/kg body weight/day, from 0.001 mg/kg body weight/day to 25 mg/kg body weight/day, from 0.001 mg/kg body weight/day to 10 mg/kg body weight/day, from 0.001 mg/kg body weight/day to 5 mg/kg body weight/day, from 0.001 mg/kg body weight/day to 1 mg/kg body weight/day, from 0.001 mg/kg body weight/day to 0.1 mg/kg body weight/day, or from 0.001 mg/kg body weight/day to 0.005 mg/kg body weight/day. Alternatively, in some embodiments the dosage range is from 0.1 g/kg body weight/day to 5 g/kg body weight/day, from 0.5 g/kg body weight/day to 5 g/kg body weight/day, from 1 g/kg body weight/day to 5 g/kg body weight/day, from 1.5 g/kg body weight/day to 5 g/kg body weight/day, from 2 g/kg body weight/day to 5 g/kg body weight/day, from 2.5 g/kg body weight/day to 5 g/kg body
weight/day, from 3 g/kg body weight/day to 5 g/kg body weight/day, from 3.5 g/kg body weight/day to 5 g/kg body weight/day, from 4 g/kg body weight/day to 5 g/kg body weight/day, or from 4.5 g/kg body weight/day to 5 g/kg body weight/day. Effective doses may be estimated from dose-response relationships derived from in vitro or animal model test bioassays or systems or from clinical trials of the P2Y 14 antagonist. The dosage should not be so large as to cause unacceptable adverse side effects.
Improvement of renal function
Providing formulations containing a P2Y 14 antagonist may improve renal function. For example, renal function may be improved by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 200%, or at least 300%. Measurable markers of renal function, are well known in the medical and veterinary literature and to those of skill in the art, and include, but are not limited to, blood urea nitrogen or "BUN" levels (both static measurements and measurements of rates of increase or decrease in BUN levels), serum creatinine levels (both static measurements and measurements of rates of increase or decrease in serum creatinine levels), measurements of the BUN/creatinine ratio (static measurements of measurements of the rate of change of the BUN/creatinine ratio),
urine/plasma ratios for creatinine, urine/plasma ratios for urea, glomerular filtration rates (GFR), serum concentrations of sodium (Na+), urine osmolarity, daily urine output, albuminuria, proteinuria, and the like. Of the above, measurements of the plasma concentrations of creatinine and/or urea or BUN are particularly important and useful readouts of renal function.
Examples
Example 1
Solutions containing PPTN were analyzed to determine the limit of quantitation by HPLC. Throughout the examples, PPTN may be referred to as KB-1801; the two terms are interchangeable.
To analyze HPLC mobility, A 0.1% trifluoroacetic acid solution was used as mobile phase A, and acetonitrile was used as mobile phase B.
FIG. 1 is a graph showing HPLC analysis of PPTN. 1 pL of a 0.1 mg/mL solution of PPTN in 50/50 acetonitrile/water was injected into the column, and the flow-through was measured by UV absorption at 268 nm. Retention time of PPTN was 2.759 minutes, and the peak area was 679,876.
FIG. 2 is a graph showing HPLC analysis of PPTN. 40 pL of a 0.01 mg/mL solution of PPTN in 50/50 acetonitrile/water injected into the column, and the flow-through was measured by UV absorption at 268 nm. Blue trace, blank sample; purple trace, 200 ng/mL; black trace, 2000 ng/mL. Results are summarized in Table 1.
Table 1.
FIG. 3 is a graph of UV absorption at 268 nm vs. concentration of PPTN (KB-1801).
Example 2
The solubility of PPTN in various aqueous and organic solvents was tested. Test media were prepared, and 5 mg/mL solid PPTN (HC1 salt) was added at room temperature. If all PPTN dissolved under these conditions, additional PPTN was added to a total of 10 mg/mL. After 24 hours, undissolved material was removed, and the concentration of PPTN in the supernatant was analyzed by HPLC. Results are summarized in Table 2.
Table 2.
DMAc = dimethylacetamide; NMP = N-methylpyrrolidone; PEG = polyethyleneglycol
The most effective solvents were dimethylacetamide and N-methylpyrrolidone>
However, the safety and utility of these solvents for formulations for intravenous infusion are unknown.
The solubility of PPTN at pH ranges suitable for intravenous injection was analyzed. PPTN (HC1 salt) was dissolved in DMSO to make a stock solution, and the stock solution was diluted into various aqueous solutions. The pH values of the diluted aqueous solutions were measured, and the solutions were observed for indications of insolubility. The solutions were then adjusted to achieve a pH > 5.0, and the solutions were observed again. Results are provided in Table 3 and Table 4.
Table 3.
Table 4.
a-Tocopherol polyethylene glycol succinate (TPGS) was tested for enhancement of solubility of PPTN at neutral pH. A solution containing 5 mg/mL PPTN and 4% TPGS was made by mixing components as indicated in Table 5 with stirring and heating. Table 5.
To create a solution suitable for in vitro studies, the solution containing 5 mg/mL PPTN and 4% TPGS created above was diluted into phosphate-buffered saline by mixing components as indicated in Table 6.
Table 6.
Example 3
The loss of PPTN due to adherence to surfaces of vessels was analyzed. PPTN is a hydrophobic compound that may adhere to plastics and other surfaces. To test how much PPTN is lost due to surface adhesion, an aqueous solution containing 200 ng/ml PPTN and less than 0.1% acetonitrile was incubated in the absence of solubilizing agent in various vessels for 24 hours. The results are shown in Table 7. Table 7.
*PA: peak area of UV absorption at 273 nm
An aqueous solution containing 5 mg/mL PPTN, 0.1% DMSO, and 0.04% TPGS in phosphate-buffered saline was incubated in the absence of additional solubilizing agent in various vessels for 16-24 hours. Results are shown in Table 8.
The results show that a substantial amount of PPTN is lost from a low-concentration solution that does not contain TPGS but not from high concentration solution that contains TPGS.
Example 4
The effect of pH on the solubility of PPTN in an aqueous medium was analyzed.
Solutions of PPTN in either water or phosphate buffer at various pH values were incubated with agitation for 24-48 hours at room temperature then filtered to remove precipitates, and the PPTN concentration of the filtered solution was analyzed. Results are shown in Table 9.
Table 9.
Example 5
Sulfobutylether-P-cyclodextrin (SBECD) was tested for the ability to increase the solubility of PPTN in aqueous media.
A stock solution containing 12% SBECD was prepared as follows: 9 mL of saline was added to 1.21 g of SBECD in a 10 mL flask, and the mixture was sonicated for 5 minutes. Saline was then added to achieve a final volume of 10 mL. The pH of the final solution was about 7.
The solubility of PPTN in solutions containing various concentrations of SBECD was analyzed. Excess PPTN was added to saline solutions containing various concentrations of SBECD, insoluble material was removed by filtration, and the PPTN concentration in the filtered solution was analyzed.
FIG. 4 is graph showing the concentration of PPTN in saturated solutions that contain different amounts of SBECD.
A solution containing 9 mg/mL PPTN was prepared as follows. 4.7 mL of 12% SBECD solution, prepared as described above, was added to a 5 mL flask containing 45 mg PPTN (HC1 salt), and the mixture was sonicated with heat for 50 minutes. After sonication, 12% SBECD solution to achieve a final volume of 5 mL. The warm solution appeared clear. The solution was allowed to cool to room temperature and was incubated at room temperature for 28 days. The solution remained clear throughout the entire incubation.
The stability of PPTN in SBECD-containing solutions was analyzed under various storage conditions. 20-mL glass vials containing 10 mL of a solution containing 9 mg/mL PPTN and 12% SBECD, as described above, were incubated under various conditions as described in Table 10.
X = time points of pulls/analyses
X† = samples prepared and put on station. HPLC analysis only if solution and/or chemical stability not good at 25°C time points. Appearance recorded at all time points.
Samples were analyzed by UHPLC-UV as described in Table 11.
Table 11.
Results of stability analysis are shown in Table 12.
* Solution viscosity increased, causing assay variability
* * Assay variability ( +6%) was observed.
FIG. 5 is a graph of PPTN (KB-1801) concentrations of samples tested in stability assay. FIG. 6 is a representative UHPLC-UV trace for the sample at 40°C, time = 28 days. The peak is PPTN (KB-1801). No degradants were evident.
All solutions retained a clear appearance with no detectable precipitation or turbidity. Freeze/thaw cycles results in an apparent change in viscosity.
The stability of PPTN in SBECD-containing solutions was analyzed at various concentrations of PPTN. A solution containing 9 mg/mL PPTN and 12% SBECD, as described above, was diluted into saline as described in Table 13.
Table 13.
The stability of high-concentration PPTN solutions containing SBECD were analyzed under conditions used for product manufacturing and distribution. A stock solution containing 8.6 mg/mL PPTN, 12% SBECD in saline was prepared as described above and shipped under refrigerated conditions. Seven days after manufacture, the stock solution was diluted to make
dosing solutions for administration as a continuous intravenous infusion as indicated in Table 14 and Table 15.
Table 14.
Table 15.
Samples of diluted dosing solutions were shipped at ambient temperature and analyzed for PPTN (KB-1801) potency and purity. Results are provided in Table 16.
Table 16.
* [KB-1801] determined by HPLC assay, single preparations, duplicate injections.
Assay results show that all samples contained PPTN (KB-1801) at slightly higher (1.6- 8.0%) than target concentrations. Samples taken from the top, middle, and bottom of the flasks in which the dilutions were performed had very similar PPTN (KB-1801) concentrations, indicating that the stock formulation is readily diluted into homogeneous solution. No evidence of degradation products was observed in any sample
The osmolarity of a stock solution containing 8.6 mg/mL PPTN, 12% SBECD in saline was analyzed. Results are provided in Table 17.
Table 17.
The pharmacokinetics of PPTN (KB-1801) in male rats receiving single bolus intravenous injections of SBECD-containing solutions were analyzed. Three cohorts of four rats each were given a single dose of PPTN (KB-1801) at 0.85 mg/kg, 2.9 mg/kg, or 8.5 mg/kg in 1 mL dosing volume.
FIG. 7 is a graph of plasma PPTN concentration over time in male rats after a single bolus injection. Dosing amounts are as indicated.
FIG. 8 is a graph of plasma PPTN concentration as a function of dose in male rats after a single bolus injection. Dosing amounts are as indicated.
FIG. 9 is a graph of urine PPTN concentration over time in male rats after a single bolus injection. Dosing amounts are as indicated.
The results show that the pharmacokinetics of plasma PPTN were well-described by a 2- compartment model (distribution and elimination), and all PK parameters were linearly dose- related. PPTN was excreted in the urine at concentrations in excess of plasma concentrations and well above those known to inhibit P2Y 14 receptor activation in vitro. PPTN/SBECD formulations were well tolerated by all rats, and no in-life adverse events reported.
Example 6
The safety and pharmacokinetics of PPTN (KB-1801) in rats receiving continuous intravenous injections of SBECD-containing solutions were analyzed. Three cohorts of six male and six female rats each were given continuous intravenous infusion of PPTN (KB-1801) at 10 mg/kg/day, 30 mg/kg/day or 100 mg/kg/day in a dosing solution containing PPTN at 0.25 mg/mL, 0.75 mg/mL or 2.5 mg/mL and SBECD at about 3.8%. Dosing volume was 40 mL/kg/day.
KB-1801 was not detectable in pooled plasma of animals infused with vehicle alone. The limit of detection was 5 ng/mL.
Plasma PPTN concentrations: results
Plasma concentrations of KB-1801 following a 24-hour intravenous infusion at 10 mg/kg to male Sprague-Dawley rats are shown in Table 18.
Table 18.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 24-hour intravenous infusion at 10 mg/kg to female Sprague-Dawley rats are shown in Table 19.
Table 19.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL) Plasma concentrations of KB-1801 following a 24-hour intravenous infusion at 30 mg/kg to male Sprague-Dawley rats are shown in Table 20.
Table 20.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 24-hour intravenous infusion at 30 mg/kg to female Sprague-Dawley rats are shown in Table 21.
Table 21.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 24-hour intravenous infusion at 100 mg/kg to male Sprague-Dawley rats are shown in Table 22.
Table 22.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 24-hour intravenous infusion at 100 mg/kg to female Sprague-Dawley rats are shown in Table 23. Table 23.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
The dose proportionality and female/male ratios at C24h are shown in Table 24. Table 24.
FIG. 10 is a graph of plasma PPTN concentration over time in rats during continuous intravenous administration for 24 hours. Dosing amounts are as indicated.
Plasma concentrations of KB-1801 following a 72-hour intravenous infusion at 10 mg/kg/day to male Sprague-Dawley rats are shown in Table 25.
Table 25.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 72-hour intravenous infusion at 10 mg/kg/day to female Sprague-Dawley rats are shown in Table 26.
Table 26.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL) Plasma concentrations of KB-1801 following a 72-hour intravenous infusion at 30 mg/kg/day to male Sprague-Dawley rats are shown in Table 27.
Table 27.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 72-hour intravenous infusion at 30 mg/kg/day to female Sprague-Dawley rats are shown in Table 28.
Table 28.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
Plasma concentrations of KB-1801 following a 72-hour intravenous infusion at 100 mg/kg to male Sprague-Dawley rats are shown in Table 29.
Table 29.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
NS: No Sample. Animal 16003 died shortly after the 24h timepoint according to CRL.
Plasma concentrations of KB-1801 following a 72-hour intravenous infusion at 100 mg/kg/day to female Sprague-Dawley rats are shown in Table 30.
Table 30.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 5.0 ng/mL)
The calculated TK parameters following 72 hours of intravenous infusion at 10, 30 and 100 mg/kg to Sprague-Dawley rats are shown in Table 31.
Table 31.
FIG. 11 is a graph of plasma PPTN concentration over time in rats during continuous intravenous administration for 72 hours. Dosing amounts are as indicated.
FIG. 12 is a graph of plasma PPTN concentration as a function of dose in rats during continuous intravenous infusion. Dosing amounts are as indicated.
Urine PPTN concentrations: results
Urine concentrations of KB-1801 following a 24-hour intravenous infusion at 10 mg/kg to male Sprague-Dawley rats are shown in Table 32.
Table 32.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL)
NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 24-hour intravenous infusion at 10 mg/kg to female Sprague-Dawley rats are shown in Table 33.
Table 33.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL)
NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 24-hour intravenous infusion at 30 mg/kg to male Sprague-Dawley rats are shown in Table 34.
Table 34.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL
NS: No sample
NC: Not calculated
Urine concentrations of KB-1801 following a 24-hour intravenous infusion at 30 mg/kg to female Sprague-Dawley rats are shown in Table 35.
Table 35.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL)
NS: No sample
NC: Not calculated
Urine concentrations of KB-1801 following a 24-hour intravenous infusion at 100 mg/kg to male Sprague-Dawley rats are shown in Table 36.
Table 36.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL)
NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 24-hour intravenous infusion at 100 mg/kg to female Sprague-Dawley rats are shown in Table 37.
Table 37.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL) NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 72-hour intravenous infusion at 10 mg/kg/day to male Sprague-Dawley rats are shown in Table 38.
Table 38.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL) NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 72-hour intravenous infusion at 10 mg/kg/day to female Sprague-Dawley rats are shown in Table 39.
Table 39.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL) NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 72-hour intravenous infusion at 30 mg/kg/day to male Sprague-Dawley rats are shown in Table 40.
Table 40.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL) NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 72-hour intravenous infusion at 30 mg/kg/day to female Sprague-Dawley rats are shown in Table 41.
Table 41.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL) NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 72-hour intravenous infusion at 100 mg/kg/day to male Sprague-Dawley rats are shown in Table 42.
Table 42.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL) NS: No sample
NC: Not calculated Urine concentrations of KB-1801 following a 72-hour intravenous infusion at 100 mg/kg/day to female Sprague-Dawley rats are shown in Table 43.
NQ: Not quantifiable. No peak or below limit of quantification (LOQ: 0.0025 pg/mL)
NS: No sample
NC: Not calculated
* Animal 16505's 44-48h sample was collected in animal 16504' s container, contaminating both samples. No volume was supplied.
Plasma PPTN concentrations: standards
Data for standard curve analysis of plasma concentrations of PPTN in rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours are shown in Tables 44-46. Table 44.
Table 45.
Table 46.
FIG. 13 is a standard curve of plasma PPTN concentrations from rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours. The standard curve is described by the equation Y = -0.000158985 + 0.000124839*X - 1.72745e 009*X2, R2 = 0.9879.
Assessment of bioanalytical acceptance criteria of plasma PPTN concentrations from rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours is provided in Table 47.
Table 47.
Data for standard curve analysis of plasma concentrations of PPTN in rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours are shown in Tables 48-50.
Table 48.
Table 49.
Table 50.
FIG. 14 is a standard curve of plasma PPTN concentrations from rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours. The standard curve is described by the equation Y = -0.000158985 + 0.000124839*X - 1.72745e 009 * X2, R2 = 0.9879
Assessment of bioanalytical acceptance criteria of plasma PPTN concentrations from rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours is provided in Table 51.
Table 51.
Data for standard curve analysis of plasma concentrations of PPTN in rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours are shown in Tables 52-54. Table 52.
Table 54.
FIG. 15 is a standard curve of plasma PPTN concentrations from rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours. The standard curve is described by the equation Y = -0.000210918 + 0.000114817*X - 2.23714e_009*X2, R2 = 0.9939.
Assessment of bioanalytical acceptance criteria of plasma PPTN concentrations from rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours is provided in Table 55.
Table 55.
Urine PPTN concentrations: standards
Data for standard curve analysis of urine concentrations of PPTN in rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours are shown in Tables 56-58.
Table 56.
Table 57.
FIG. 16 is a standard curve of urine PPTN concentrations from rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours. The standard curve is described by the equation Y = -0.000176376 + 0.0595859*X - 3.46151e-005*X2, R2 = 0.9900.
Assessment of bioanalytical acceptance criteria of urine PPTN concentrations from rats that received continuous intravenous infusion at 10 mg/kg for 24 or 72 hours is provided in Table 59.
Table 59.
Data for standard curve analysis of urine concentrations of PPTN in rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours are shown in Tables 60-62.
Table 61.
Table 62.
FIG. 17 is a standard curve of urine PPTN concentrations from rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours. The standard curve is described by the equation Y = -0.00377387 + 0.0604135*X - 3.10066e 005*X2, R2 = 0.9920.
Assessment of bioanalytical acceptance criteria of urine PPTN concentrations from rats that received continuous intravenous infusion at 30 mg/kg for 24 or 72 hours is provided in Table 63.
Table 63.
Data for standard curve analysis of urine concentrations of PPTN in rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours are shown in Tables 64-66.
Table 64.
Table 66.
FIG. 18 is a standard curve of urine PPTN concentrations from rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours. The standard curve is described by the equation Y = -0.000176376 + 0.0595859*X - 3.46151e 005*X2, R2= 0.9900.
Assessment of bioanalytical acceptance criteria of urine PPTN concentrations from rats that received continuous intravenous infusion at 100 mg/kg for 24 or 72 hours is provided in Table 67.
Table 67.
Data for standard curve analysis of a summary of urine concentrations of PPTN in rats that received continuous intravenous infusion for 24 or 72 hours are shown in Tables 68-70. Table 68.
Table 69.
Table 70.
Summaries
FIG. 19 is a standard curve of of a summary of urine concentrations of PPTN in rats that received continuous intravenous infusion for 24 or 72 hours. The standard curve is described by the equation Y = -0.000295157 + 0.000508402*X2, R2= 0.9923.
Assessment of bioanalytical acceptance criteria of a summary of urine concentrations of PPTN in rats that received continuous intravenous infusion for 24 or 72 hours is provided in Table 71. Table 71.
A summary of the plasma analytical method is provided in Table 72.
Table 72.
A summary of the urine analytical method is provided in Table 73.
Table 73.
The results show that during continuous intravenous infusion plasma PPTN
concentrations reached steady state within approximately 24 hours and that PPTN concentrations were linearly dose-related. Plasma PPTN concentrations were reduced 10-fold to 30-fold within
24 hours after discontinuation of a 72-hour continuous infusion. PPTN was excreted in the urine at concentrations generally in excess of plasma concentrations and well above those known to inhibit P2Y 14 receptor activation in vitro. PPTN/SBECD formulations were well tolerated by all rats; no adverse events or observations reported in-life, at necropsy, in blood clinical chemistry or cell count analyses.
Incorporation by Reference
References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, have been made throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes.
Equivalents
Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification, and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.
Claims
1. A pharmaceutical formulation comprising a naphthoic acid derivative or salt thereof and an agent selected from the group consisting of a-tocopherol polyethylene glycol succinate (TPGS) and sulfobutyl ether beta-cyclodextrin (SBECD).
2. The pharmaceutical formulation of claim 1, wherein the naphthoic acid derivative is 4- ((piperidin-4-yl)-phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (PPTN).
3. The pharmaceutical formulation of claim 1, wherein the naphthoic acid derivative salt is PPTN hydrochloride.
4. The pharmaceutical formulation of claim 1, wherein a pH of the pharmaceutical formulation is greater than 5.0.
5. The pharmaceutical formulation of claim 1, wherein the naphthoic acid derivative is present at > 0.2 mg/ml.
6. The pharmaceutical formulation of claim 1, wherein the agent is TPGS and the pharmaceutical formulation further comprises saline or phosphate buffered saline (PBS).
7. The pharmaceutical formulation of claim 6, wherein the TPGS is present at less than
10%.
8. The pharmaceutical formulation of claim 6, wherein the pharmaceutical formulation further comprises DMSO.
9. The pharmaceutical formulation of claim 8, wherein the DMSO is present at less than
1%.
10. The pharmaceutical formulation of claim 1, wherein the agent is SBECD.
11. The pharmaceutical formulation of claim 10, wherein the pharmaceutical formulation further comprises saline or phosphate buffered saline (PBS).
12. The pharmaceutical formulation of claim 10, wherein the SBECD is present at less than
20%.
13. The pharmaceutical formulation of claim 10, wherein the SBECD is present at less than
10%.
14. The pharmaceutical formulation of claim 10, wherein the SBECD is present at less than 5%.
15. A method for treating a renal disorder, the method comprising providing to a subject a pharmaceutical formulation comprising a naphthoic acid derivative or salt thereof and an agent selected from the group consisting of a- tocopherol polyethylene glycol succinate (TPGS) and sulfobutyl ether beta-cyclodextrin (SBECD).
16. The method of claim 15, wherein the naphthoic acid derivative is 4-((piperidin-4-yl)- phenyl)-(7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid (PPTN).
17. The method of claim 15, wherein the naphthoic acid derivative salt is PPTN
hydrochloride.
18. The method of claim 15, wherein a pH of the pharmaceutical formulation is greater than 5.0.
19. The method of claim 15, wherein the agent is TPGS and the pharmaceutical formulation further comprises saline or phosphate buffered saline (PBS).
20. The method of claim of claim 19, wherein the TPGS is present at less than 10%.
21. The method of claim 19, wherein the pharmaceutical formulation further comprises DMSO.
22. The method of claim 21, wherein the DMSO is present at less than 1%.
23. The method of claim 15, wherein the agent is SBECD.
24. The method of claim 23, wherein the SBECD is present at less than 20%.
25. The method of claim 23, wherein the SBECD is present at less than 10%.
26. The method of claim 23, wherein the SBECD is present at less than 5%.
27. The method of claim 15, wherein the pharmaceutical formulation further comprises saline or phosphate buffered saline (PBS
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20791056.3A EP3955907A4 (en) | 2019-04-16 | 2020-04-13 | Pharmaceutical formulations containing p2y14 antagonists |
US17/601,855 US20220202799A1 (en) | 2019-04-16 | 2020-04-13 | Pharmaceutical formulations containing p2y14 antagonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962834517P | 2019-04-16 | 2019-04-16 | |
US62/834,517 | 2019-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020214510A1 true WO2020214510A1 (en) | 2020-10-22 |
Family
ID=72838387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/027882 WO2020214510A1 (en) | 2019-04-16 | 2020-04-13 | Pharmaceutical formulations containing p2y14 antagonists |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220202799A1 (en) |
EP (1) | EP3955907A4 (en) |
WO (1) | WO2020214510A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180136237A1 (en) * | 2013-11-07 | 2018-05-17 | The General Hospital Corporation | Compositions and methods for detecting and/or treating inflammation |
US20180318210A1 (en) * | 2015-11-06 | 2018-11-08 | Carinopharm Gmbh | Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate |
WO2019204283A1 (en) * | 2018-04-16 | 2019-10-24 | Kantum Diagnostics, Inc. | Methods of monitoring, treating, and preventing renal inflammation associated with kidney transplantation |
-
2020
- 2020-04-13 EP EP20791056.3A patent/EP3955907A4/en active Pending
- 2020-04-13 US US17/601,855 patent/US20220202799A1/en active Pending
- 2020-04-13 WO PCT/US2020/027882 patent/WO2020214510A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180136237A1 (en) * | 2013-11-07 | 2018-05-17 | The General Hospital Corporation | Compositions and methods for detecting and/or treating inflammation |
US20180318210A1 (en) * | 2015-11-06 | 2018-11-08 | Carinopharm Gmbh | Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate |
WO2019204283A1 (en) * | 2018-04-16 | 2019-10-24 | Kantum Diagnostics, Inc. | Methods of monitoring, treating, and preventing renal inflammation associated with kidney transplantation |
Non-Patent Citations (1)
Title |
---|
DATABASE PUBCHEM Substance [online] 5 September 2016 (2016-09-05), "PPTN hydrochloride", XP055750303, retrieved from ncbi Database accession no. SID 316958787 * |
Also Published As
Publication number | Publication date |
---|---|
EP3955907A1 (en) | 2022-02-23 |
EP3955907A4 (en) | 2022-12-28 |
US20220202799A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10639305B2 (en) | Liquid preparation comprising pimobendan | |
Pflueger et al. | Role of Adenosine in Contrast media—induced Acute Renal Failure in diabetes mellitus | |
Laniado-Laborín et al. | Amphotericin B: side effects and toxicity | |
AU2013259526B2 (en) | New methods | |
Anderson et al. | Dapagliflozin for the treatment of type 2 diabetes | |
US9572887B2 (en) | Formulations of bendamustine | |
Benoehr et al. | Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial | |
ES2743769T3 (en) | Medicinal treatment of dermal diseases in pets with norketotifen | |
KR20090094090A (en) | Methods and compositions for therapeutic treatment | |
WO2013067396A2 (en) | Administration of nedd8-activating enzyme inhibitor and hypomethylating agent | |
US20210046332A1 (en) | Ambrisentan for use in the treatment of acute renal failure | |
PT1646425E (en) | Parasiticidal composition | |
Harry et al. | Efficacy of 4-methylpyrazole in ethylene glycol poisoning: clinical and toxicokinetic aspects | |
WO2015069948A1 (en) | Novel methods | |
WO2020214510A1 (en) | Pharmaceutical formulations containing p2y14 antagonists | |
WO1999043324A1 (en) | Preventives or remedies for drug-induced renal disturbance | |
NZ746140B2 (en) | Ambrisentan for use in the treatment of acute renal failure | |
Lin et al. | Renal Protective Agents in Trauma and Critical Care | |
KR20160038058A (en) | Preventative and therapeutic agent for diabetic nephropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20791056 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020791056 Country of ref document: EP Effective date: 20211116 |